at Investor's Business Daily (Jan 20, 2015)
Johnson & Johnson's (JNJ -0.2%) says Simponi, its drug for hard to treat ulcerative colitis being produced by subsidiary Janssen Biotech, has received FDA approval. The injectable drug is used to induce and maintain remission from the chronic inflammatory bowel disease, which is marked by inflammation and ulceration of the innermost lining of the colon.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Zacks.com (Jan 20, 2015)
at CNBC.com (Jan 20, 2015)
Pre-Market Earnings Report for January 20, 2015 : JNJ, MS, DAL, HAL, BHI, MTB, RF, IGTE, ATI, EDU, MTG, SAPat Nasdaq.com (Jan 16, 2015)
at CNBC.com (Jan 16, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs